Skip to main content
SpringerLink
Log in

Olverembatinib: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs. In November 2021, olverembatinib received its first approval in China for the treatment of adult patients with TKI-resistant chronic-phase CML (CML-CP) or accelerated-phase CML (CML-AP) harbouring the T315I mutation, as confirmed by a validated diagnostic test. Clinical studies are underway in the US for CML and precursor cell ALL, and in China for solid tumours, including GIST. This article summarizes the milestones in the development of olverembatinib leading to this first approval for the treatment of CML-CP or CML-AP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alves R, Goncalves AC, Rutella S, et al. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance. Cancers. 2021;13(19):4820.

    Article  CAS  Google Scholar 

  2. Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530–42.

    Article  CAS  Google Scholar 

  3. Javidi-Sharifi N, Hobbs G. Future directions in chronic phase CML treatment. Curr Hematol Malig Rep. 2021;16(6):500–8.

    Article  Google Scholar 

  4. Shoukier M, Kubiak M, Cortes J. Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Curr Oncol Rep. 2021;23(8):91.

    Article  CAS  Google Scholar 

  5. Ren X, Pan X, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013;56(3):879–94.

    Article  CAS  Google Scholar 

  6. Jiang Q, Dayu S, Zongru L, et al. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I-mutated chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP). Blood. 2021;138(Suppl 1):3598.

    Google Scholar 

  7. Ascentage Pharma. Ascentage Pharma and Innovent Biologics announce approval for China’s first third-generation BCR-ABL TKI olverembatinib, marking a clinical breakthrough in the treatment of chronic myeloid leukemia [media release]. 30 Nov 2021. https://www.ascentagepharma.com/press-releases/ascentage-pharma-and-innovent-biologics-announce-approval-for-chinas-first-third-generation-bcr-abl-tki-olverembatinib-marking-a-clinical-breakthrough-in-the-treatment-of-chronic-myeloid-leu-2/.

  8. Ascentage Pharma. Olverembatinib (HQP1351): Chinese prescribing information. 2021

  9. Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences. http://english.gibh.cas.cn/Comment/201305/t20130527_102502.html. Accessed 20 Dec 2021.

  10. Ascentage Pharma. 2019 Annual report. https://www.ascentagepharma.com/wp-content/uploads/2020/08/2020041700666.pdf. Accessed 20 Dec 2021.

  11. Ascentage Pharma, MD Anderson Cancer Center. Ascentage Pharma and MD Anderson Cancer Center announce strategic alliance in cancer drug development [media release]. 6 Jan 2019. https://www.ascentagepharma.com/news/press-releases/.

  12. Innovent Biologics. Ascentage Pharma and Innovent Biologics reach multifaceted strategic agreement totaling US$245 million including commercialization of olverembatinib (HQP1351) in China, joint clinical development of lisaftoclax (APG-2575) and equity investment [media release]. 14 Jul 2021. https://www.ascentagepharma.com/news/press-releases/.

  13. Wang Y, Zhang L, Tang X, et al. GZD824 as a FLT3, FGFR1 and PDGFRα inhibitor against leukemia in vitro and in vivo. Transl Oncol. 2020;13(4):100766.

    Article  Google Scholar 

  14. Liu X, Wang G, Yan X, et al. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019;9:88.

    Article  Google Scholar 

  15. Jiang Q, Huang XJ, Chen Z, et al. Safety and efficacy of HQP1351, a 3rd generation oral BCR-ABL inhibitor in patients with tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: preliminary results of phase I study [abstract]. Blood. 2018;132(Suppl. 1):791.

    Article  Google Scholar 

  16. Ye W, Jiang Z, Lu X, et al. GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways. Oncotarget. 2017;8(50):87002–15.

    Article  Google Scholar 

  17. Jiang K, Tang X, Guo J, et al. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. Cancer Med. 2021;10(14):4874–84.

    Article  CAS  Google Scholar 

  18. Fang DD, Zhu H, Tang Q, et al. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Transl Oncol. 2021;15(1):101244.

    Article  Google Scholar 

  19. Wang G, Lv J, Tang C, et al. ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance conferred by the compound mutations of BCR-ABL [abstract]. Cancer Res. 2021;81(13 Suppl):1463.

    Google Scholar 

  20. Fang DD, Tang Q, Wang Q, et al. Synergy of tyrosine kinase inhibitor HQP1351 and MDM2-P53 antagonist, APG-115, in preclinical models of FLT3 mutant and TP53 wild-type acute myeloid leukemia [abstract]. Cancer Res. 2020;80(16 Suppl):4217.

  21. Jiang Q, Huang X, Chen Z, et al. An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3rd generation of BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI resistant chronic myeloid leukemia [abstract]. Blood. 2019;134(Suppl 1):493.

    Article  Google Scholar 

  22. Lu M, Deng C, Xiong Y, et al. Exposure-response (E-R) analysis of olverembatinib (HQP1351) in Chinese patients with chronic myeloid leukemia (CML) [abstract]. Blood. 2020;136(Suppl 1):5–6.

    Google Scholar 

  23. Jiang Q, Shi D, Li Z, et al. Updated safety and efficacy results of phase 1 study of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) [abstract plus presentation]. Blood. 2021;138(Suppl 1):311.

    Google Scholar 

  24. Jabbour EJ, Kantarjian H, Issa GC, et al. Trial in Progress: Phase 1b bridging study of the pharmacokinetics (PK), safety, and efficacy of orally administered olverembatinib (HQP1351) in patients with refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [abstract]. Blood. 2021;138(Suppl 1):2551.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 502 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Olverembatinib: First Approval. Drugs 82, 469–475 (2022). https://doi.org/10.1007/s40265-022-01680-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-022-01680-9

Search

Navigation